Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KITE-439 in HPV16+ Cancers
NCT03912831Phase 1Terminated
- Sponsor
- Gilead Sciences
- Start
- Apr 2019
- Primary completion
- Feb 2022
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of KITE-439 in cancer (7 arms), sponsored by Gilead Sciences. Primary endpoints: Dose-Limiting Toxicities at 21 days and Objective Response Rate at 1.4 years. Started Apr 2019; status: terminated.
02
Drugs
KITE-439
03
Conditions
cancer
Beyond the preview
Go deeper on NCT03912831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03912831.